Please provide your email address to receive an email when new articles are posted on . The novel gene therapy is aimed at optogenetic vision restoration in diseases causing blindness. The Series A ...

Please provide your email address to receive an email when new articles are posted on . Study participants with advanced retinitis pigmentosa who received MCO-010 experienced improvements in vision.

Add Futurism (opens in a new tab) More information Adding us as a Preferred Source in Google by using this link indicates that you would like to see more of our content in Google News results.

Nanoscope Therapeutics is back with more data assessing its gene therapy that uses light-sensitive molecules to treat retinal disease. With data demonstrating vision improvement in hand, the biotech ...

DALLAS, March 30, 2026 /PRNewswire/ -- Nanoscope Therapeutics, Inc., a biotechnology company committed to developing and commercializing novel, disease-agnostic therapies for patients with ...

Gene therapy emerges as a transformative force in ophthalmology, offering renewed hope for patients with retinal diseases. This innovative approach targets both inherited and acquired conditions, ...

Six-Month Clinical Data Demonstrate Restoration of Cone-Mediated Vision in Pediatric LCA5 Patients, with Sensitivity Improvements Reaching Normal ...